版本:
中国

BRIEF-Versartis Inc presents 3-year somavaratan safety and efficacy data

May 22 Versartis Inc

* Versartis presents 3-year somavaratan safety and efficacy data and pediatric program baseline demographics at the 19th European congress of endocrinology

* Three-year results support 3.5 mg/kg twice-monthly dose regimen being used in ongoing phase 3 velocity trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐